Rhythm Pharmaceuticals, Inc. RYTM
98.66
0.35
0.36%
as of 25 Sep
- Market cap
- $6.8B
- P/E
- 0.0×
Follow RYTM
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (461.65%) | (293.04%) | (251.14%) | (247.13%) |
+8 more TTM periods Free account |
|
| (51.91%) | (50.14%) | (46.29%) | (45.44%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(69.36%) | (63.37%) | (55.77%) | (50.60%) | |
Average Days of Receivables |
61.47 | 57.47 | 50.17 | 69.16 | |
Free Cash Flow per Share |
(1.54) | (1.76) | (2.42) | (2.26) | |
Free Cash Flow |
(105.35) | (119.51) | (157.13) | (149.63) | |
Capital Expenditures |
— | — | (41.45) | (40.50) | |
Piotroski F-Score |
3.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(19.22%) | (20.67%) | (17.55%) | (15.33%) | |
Accounts Receivable Turnover |
7.21 | 8.35 | 8.51 | 6.66 | |
Accounts Payable Turnover |
1.64 | 1.90 | 1.48 | 2.00 | |
Inventory Turnover |
1.07 | 0.96 | 0.88 | 1.03 | |
Average Days of Payables |
223.59 | 195.17 | 261.17 | 269.29 | |
Days of Inventory on Hand |
422.10 | 454.66 | 482.24 | 436.73 | |
Tax Rate |
0.01 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
72.20% | 79.24% | 88.19% | 95.49% | |
Selling, General and Administrative Expense of Revenue |
100.43% | 101.05% | 102.73% | 100.72% | |
Share Based Compensation of Revenue |
36.36% | 35.48% | 35.21% | 33.33% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.50 | 0.58 | 0.57 | 0.55 | |
Depreciation/Fixed assets |
10.48 | 1.13 | 1.21 | 6.11 | |
Capex/Depreciation |
0.00 | 0.00 | (30.98) | (27.95) | |
Revenue per Share |
3.50 | 3.19 | 2.92 | 2.63 | |
Operating CF per Share |
(1.54) | (1.76) | (1.78) | (1.65) | |
Capex per Share |
0.00 | 0.00 | (0.64) | (0.61) | |
Capex to Sales |
0.00 | 0.00 | 0.22 | 0.23 | |
Net Profit Margin |
(87.62%) | (95.71%) | (106.41%) | (113.43%) |
Columns are period end dates